Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The "no Biopsy Approach" for Heart Transplantation Follow-up

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03959579
Recruitment Status : Completed
First Posted : May 22, 2019
Last Update Posted : May 22, 2019
Sponsor:
Information provided by (Responsible Party):
Centre Chirurgical Marie Lannelongue

Brief Summary:

Pathological analysis is the gold standard for diagnosis of acute allograft rejection after heart transplantation (HTx). This method requires repeated endomyocardial biopsies during the first post-operative year. However the sensitivity of endomyocardial biopsy (EMB) is not perfect and can be associated with major complications including fatal tamponade. Moreover, repeated biopsies are associated with reduced quality of life for HTx recipients.

Since almost 20 years, the investigators do not perform routinely EMB for acute rejection screening. Early left ventricular diastolic dysfunction was investigated according to a standardized protocol. The investigators sought to analyze the long-term post-transplant outcomes without systematic EMB. The investigators hypothesize that exclusive echographic screening was not associated with impaired outcomes.


Condition or disease Intervention/treatment
Cardiac Transplant Rejection Diagnostic Test: systematic endomyocardial biopsy.

Detailed Description:

Demographic characteristics of heart transplant recipients and organ donors were prospectively collected in a local database. All HTx successively performed in the Hospital Marie Lannelongue from 1990 to 2016 were included. From 1990 to 1997, both EMB and cardiac echo were routinely performed at each medical follow-up date. After 1997, only cardiac echo was used to detect early acute allograft rejection. The investigators collected the results of all EMB and synchronous cardiac echo in patients transplanted between 1990 and 1997 (group A, validation cohort), and clinical events and long-term survival in patients transplanted from 1998 to 2016 (group B, standardization cohort). For our purpose, the investigators graded the histological patterns of acute cardiac rejection according to the 1990 international classification. Cardiac echo assessment included the isovolumic relaxation time, E-wave velocity and E/A ratio. Impaired left ventricular relaxation was consistent with acute cardiac rejection.

The investigators therefore analyzed the rate of positive and negative EMB during the first post-transplant year and compared these results to the synchronous cardiac echo report in group A. Sensibility and specificity of cardiac echo to detect acute cardiac rejection were calculated. The rate of acute cardiac rejection during the first year was collected in group B and compared to group A. Finally, long-term survival was analyzed according to the Kaplan-Meier approach and compared between group A and B (log-rank test). The investigators hypothesize that the participant will not observe any differences between groups considering the rate of acute cardiac rejection during the first year. In addition, the investigators do not expect to find any significant difference in long-term survival between the two cohorts. These findings may have a major impact on HTx follow-up since systematic EMB could be replaced by a standardized cardiac echo protocol focusing on left ventricular wall relaxation. EMB should therefore only be indicated in case of acute allograft dysfunction without evidence of rejection on conventional cardiac echo.


Layout table for study information
Study Type : Observational
Actual Enrollment : 269 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Long-term Outcomes After Non-invasive Assessment of Acute Cardiac Rejection in Heart Transplantation : the Marie Lannelongue Hospital Experience
Actual Study Start Date : November 22, 2017
Actual Primary Completion Date : March 31, 2018
Actual Study Completion Date : March 31, 2018

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
1st cohort = "derivation cohort":
1st cohort = "derivation cohort": 1990-1998: cardiac echo + simultaneous systematic endomyocardial biopsy
Diagnostic Test: systematic endomyocardial biopsy.

We sought to compare the long term survival of HTx recipients followed with or without systematic endomyocardial biopsy. Second, the sensibility and specificity of cardiac echo to diagnose acute allograft rejection will be analyzed.

To show the safety of non-invasively monitoring HTx recipients without systematic endomyocardial biopsy


2nd cohort = "validation cohort"
2nd cohort = "validation cohort": 1999-2016: only cardiac echo with same protocol (endomyocardial biopsy only in case of doubt)



Primary Outcome Measures :
  1. Long-term survival [ Time Frame: 15 years ]
    Survival of patients


Secondary Outcome Measures :
  1. Sensitivity [ Time Frame: 15 years ]
    Sensitivity of Cardiac Ultrasound to Diagnose Acute Heart Releases in the 1st Group

  2. Specificity [ Time Frame: 15 years ]
    Specificity of Cardiac Ultrasound to Diagnose Acute Heart Releases in the 1st Group

  3. Positive Predictive Value [ Time Frame: 15 years ]
    Positive Predictive Value of Cardiac Ultrasound to Diagnose Acute Heart Releases in the 1st Group

  4. Negative Predictive Value [ Time Frame: 15 years ]
    Negative Predictive Value of Cardiac Ultrasound to Diagnose Acute Heart Releases in the 1st Group


Other Outcome Measures:
  1. Incidence of long-term complications [ Time Frame: 15 years ]
    Incidence of chronic cardiac rejection (coronary disease of the graft), retransplantation rate



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
269 patients (alive and deceased) patients transplanted between 1990 and 1998 and 1999 and 2016
Criteria

Inclusion Criteria:

  • All heart transplant patients, including heart / liver and heart / kidney, and followed at Marie Lannelongue Hospital
  • Transplantations carried out between 01/01/1990 and 31/12/2006
  • Major and minor patients

Exclusion Criteria:

  • Patient with missing test data (cardiac ultrasound or endomyocardial biopsy)
  • Patient who did not simultaneously benefit from cardiac ultrasound and endomyocardial biopsy (Delayed period of +/- 1 days)
  • Patient who had an endomyocardial biopsy without cardiac ultrasound the day before or the day after endomyocardial biopsy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03959579


Locations
Layout table for location information
France
Hopital Marie Lannelongue
Le Plessis-Robinson, France, 92350
Sponsors and Collaborators
Centre Chirurgical Marie Lannelongue
Investigators
Layout table for investigator information
Principal Investigator: Julien Guihaire, MD, PhD Marie Lannelongue Hospital

Layout table for additonal information
Responsible Party: Centre Chirurgical Marie Lannelongue
ClinicalTrials.gov Identifier: NCT03959579     History of Changes
Other Study ID Numbers: 2017-28
First Posted: May 22, 2019    Key Record Dates
Last Update Posted: May 22, 2019
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No